European Union - English - EMA (European Medicines Agency)

valneva austria gmbh - japanese-encephalitis virus, inactivated (attenuated strain sa14-14-2 grown in vero cells) - encephalitis, japanese; immunization - vaccines - ixiaro is indicated for active immunisation against japanese encephalitis in adults, adolescents, children and infants aged two months and older.ixiaro should be considered for use in individuals at risk of exposure through travel or in the course of their occupation.

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - tick-borne encephalitis virus (inactivated) neudoerfl - suspension for injection in pre-filled syringe - 0.25 millilitre(s) - encephalitis vaccines; encephalitis, tick borne, inactivated, whole virus - encephalitis vaccines - it is indicated for the active (prophylactic) immunization of children aged from 1 year to 15 years against tick-borne encephalitis (tbe).

Ireland - English - HPRA (Health Products Regulatory Authority)

pfizer healthcare ireland - tbe virus antigen - suspension for injection in pre-filled syringe - 0.5 millilitre(s) - encephalitis vaccines; encephalitis, tick borne, inactivated, whole virus - encephalitis vaccines - it is indicated for the active (prophylactic) immunization of persons of 16 years of age and older against tick-borne encephalitis (tbe).

Australia - English - Department of Health (Therapeutic Goods Administration)

biocelect pty ltd - japanese encephalitis virus, quantity: 4 pfu - injection, powder for - excipient ingredients: albumin; mannitol; glutamic acid; histidine; sodium chloride; potassium hydroxide; lactose monohydrate; water for injections - imojev is indicated for prophylaxis of japanese encephalitis caused by the japanese encephalitis virus, in individuals from 9 months of age and over.

Australia - English - Department of Health (Therapeutic Goods Administration)

seqirus pty ltd - japanese encephalitis virus, quantity: 6 agu - injection, suspension - excipient ingredients: aluminium hydroxide hydrate; sodium chloride; monobasic potassium phosphate; dibasic sodium phosphate; water for injections - jespect is indicated for active immunisation against japanese encephalitis (je) virus for persons 18 years of age and older. jespect should be considered for use in persons who plan to reside in or travel to areas where je is endemic (common) or epidemic (seasonal), especially during the transmission season. jespect is indicated for persons who work with je virus in laboratories and in industry.

New Zealand - English - Ministry for Primary Industries

new zealand bloodstock ltd - japanese encephalitis virus - japanese encephalitis virus 0 vaccine - vaccine

Canada - English - Health Canada

valneva austria gmbh - inact.japanese encephal virus(attenuat. strain sa14-14-2 produced in vero cells) - suspension - 6mcg - inact.japanese encephal virus(attenuat. strain sa14-14-2 produced in vero cells) 6mcg - vaccines

Ireland - English - HPRA (Health Products Regulatory Authority)

gsk vaccines gmbh - inactivated rabies virus - powder and solvent for solution for injection - 2.5 international unit(s)/millilitre - rabies vaccines; rabies, inactivated, whole virus

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis a virus, quantity: 50 u/ml - injection - excipient ingredients: aluminium; water for injections; borax; sodium chloride - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 12 months of age and older. primary immunisation should be given at least 2 weeks prior to expected exposure to hepatitis a virus. individuals who are or will be increased risk of infection include: travellers to areas of intermediate or high endemicity for hepatitis a. persons for whom hepatitis a is an occupational hazard. employee of child day-care centers. certain institutional workers (eg. caretakers for the intellectually disabled). health workers and teachers in remote aboriginal and torres strait islander communities. nursing staff and other health care workers in contact with patients in paediatric wards and infectious disease wards. sewerage workers. recipients of blood products. individuals with chronic liver disease and those who have had a liver transplant. homosexually active males. human immunodeficiency virus (hiv)-infected adults.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck sharp & dohme (australia) pty ltd - hepatitis a virus, quantity: 50 u/ml - injection - excipient ingredients: borax; aluminium; sodium chloride; water for injections - vaqta is indicated for active pre-exposure prophylaxis against disease caused by hepatitis a virus in persons 12 months of age and older. primary immunisation should be given at least 2 weeks prior to expected exposure to hepatitis a virus. individuals who are or will be increased risk of infection include: travellers to areas of intermediate or high endemicity for hepatitis a. persons for whom hepatitis a is an occupational hazard. employee of child day-care centers. certain institutional workers (eg. caretakers for the intellectually disabled). health workers and teachers in remote aboriginal and torres strait islander communities. nursing staff and other health care workers in contact with patients in paediatric wards and infectious disease wards. sewerage workers. recipients of blood products. individuals with chronic liver disease and those who have had a liver transplant. homosexually active males. human immunodeficiency virus (hiv)-infected adults.